Like Vertex Pharmaceuticals, but exclusively focused on developing gene therapies for rare genetic diseases.

Similar to BioMarin Pharmaceutical, but specializing in cutting-edge gene therapy approaches for rare disorders.

• Gene therapy for Fanconi Anemia: An ex vivo lentiviral vector program targeting a genetic bone marrow defect affecting blood cell production.
• Gene therapy for Leukocyte Adhesion Deficiency-I: An ex vivo lentiviral vector program addressing a genetic disorder that impairs the immune system.
• Gene therapy for Pyruvate Kinase Deficiency: An ex vivo lentiviral vector program for a rare red blood cell disorder causing chronic hemolytic anemia.
• Gene therapy for Danon Disease: An in vivo adeno-associated virus program for a multi-organ lysosomal disorder leading to heart failure.

Rocket Pharmaceuticals (RCKT) operates as a biotechnology company focused on developing gene therapies for rare and devastating diseases. Given the nature of its products, which are specialized medical treatments, the company primarily sells to other companies and institutions within the healthcare sector rather than directly to individuals.

While specific customer names are not disclosed in the provided information, the company's approved gene therapies would typically be sold to the following categories of organizations:

• Hospitals and Specialized Medical Centers: These institutions are the primary purchasers and administrators of complex gene therapies for patients requiring treatment for the rare diseases Rocket Pharmaceuticals targets (e.g., Fanconi Anemia, Danon disease).
• Specialty Pharmacies and Pharmaceutical Distributors: These companies handle the distribution, logistics, and often patient support services for high-cost, specialized biological products like gene therapies, facilitating their delivery from the manufacturer to healthcare providers.

• REGENXBIO, Inc. (RGNX)

Gaurav Shah, MD, Chief Executive Officer and Corporate Board Member

Dr. Gaurav Shah is a co-founder of Rocket Pharmaceuticals and serves as its Chief Executive Officer and Corporate Board Member. Before co-founding Rocket, Dr. Shah was a Global Program Head in the Cell & Gene Therapies Unit at Novartis, where he oversaw strategic initiatives across 12 functions and helped lead pivotal trials for patients with leukemia and lymphoma, contributing to the FDA approval of Kymriah. His career at Novartis also included roles as Global Clinical Program Head for CART-19 and Biosimilars, and lead physician for Afinitor. Dr. Shah started his industry career at ImClone/Eli Lilly as a Medical Director, where he managed oncology trials focused on monoclonal antibodies. Rocket Pharmaceuticals was seeded in July 2015 with RTW Investments as a lead investor.

Martin Wilson, JD, Interim Principal Financial Officer, General Counsel & Chief Corporate Officer

Martin Wilson serves as the interim Principal Financial Officer for Rocket Pharmaceuticals, a role he assumed effective September 8, 2025, following the resignation of the previous CFO. He also holds the titles of General Counsel and Chief Corporate Officer, having been appointed General Counsel and Chief Compliance Officer in November 2021 and Chief Corporate Officer in March 2024. In his current capacity, Mr. Wilson leads Legal, Compliance, and Corporate Development, working to advance Rocket's corporate strategy.

Kinnari Patel, Pharm.D., MBA, President, Head of R&D, and Chief Operating Officer

Kinnari Patel has been named President, Head of R&D, and continues as Chief Operating Officer for Rocket Pharmaceuticals. She joined Rocket in 2016, drawn by the company's focus on developing potentially curative therapies for rare pediatric diseases. Her passion for making rare disease drug development more efficient began with a student rotation at the Office of Orphan Product Development at the FDA in 2004. Ms. Patel worked with Dr. Gaurav Shah in prior roles before joining Rocket Pharmaceuticals.

Jonathan Schwartz, MD, Chief Medical & Gene Therapy Officer

Jonathan Schwartz holds the position of Chief Medical & Gene Therapy Officer at Rocket Pharmaceuticals. He joined Rocket in 2016, motivated by the opportunity to work on cutting-edge science that addresses the root cause of diseases. Prior to this role, Dr. Schwartz was Vice President for Clinical Development at Stemline Therapeutics, overseeing early development efforts for various anticancer platforms. He also had a seven-year tenure at ImClone/Eli Lilly, where he led the development of the antiangiogenic monoclonal antibody Ramucirumab (CYRAMZA) through its Phase 3 program, leading to FDA and international approvals for stomach, lung, and colorectal cancers. Dr. Schwartz also participated in the multi-stage development of several other monoclonal antibodies. He previously served as an Associate Professor of Medicine at the Mount Sinai Medical Center, specializing in hepatobiliary malignancies and directing the Hematology-Oncology Fellowship training program. Dr. Schwartz also worked with Dr. Gaurav Shah in previous roles.

Sarbani Chaudhuri, Chief Commercial & Medical Affairs Officer

Sarbani Chaudhuri serves as the Chief Commercial & Medical Affairs Officer for Rocket Pharmaceuticals.

1. Clinical Trial Failures and Patient Safety Events: Rocket Pharmaceuticals faces significant risks associated with the safety and efficacy of its investigational gene therapies. A prominent example is the patient death in the Phase 2 pivotal trial for RP-A501, its gene therapy candidate for Danon disease, which led to a clinical hold by the U.S. Food and Drug Administration (FDA) in May 2025. This serious adverse event, linked to an acute systemic infection and complications from capillary leak syndrome, caused a substantial drop in the company's stock price and highlighted the unpredictable nature of serious safety events in gene therapy. While the FDA lifted the clinical hold in August 2025 following protocol amendments, including the removal of a novel immunosuppressant and a lower dose, the potential for further adverse events or trial setbacks remains a critical concern for both the specific program and the company's broader gene therapy platform.
2. Regulatory Delays, particularly Manufacturing and Chemistry, Manufacturing, and Controls (CMC) Issues: The company has experienced regulatory setbacks related to manufacturing processes. In June 2024, the FDA issued a Complete Response Letter (CRL) for the Biologics License Application (BLA) of Kresladi (RP-L201), Rocket's gene therapy for Leukocyte Adhesion Deficiency-I (LAD-I). The CRL requested additional information on Chemistry, Manufacturing, and Controls (CMC). A second CRL, if issued, could significantly delay the therapy's launch, potentially pushing it past the Priority Review Voucher (PRV) sunset date and resulting in a loss of substantial value. This underscores the complex and stringent regulatory requirements, particularly concerning the manufacturing readiness of gene therapies.
3. Funding and Commercialization Risks: As a biotechnology company without marketed products, Rocket Pharmaceuticals is inherently exposed to significant funding and commercialization risks. The company is currently unprofitable and is not projected to achieve profitability within the next three years. Rocket is actively burning through its cash reserves, making its ability to secure future funding, potentially through Priority Review Vouchers (PRVs) or strategic partnerships, crucial for sustaining its research and development efforts. The recent clinical setbacks, particularly the patient death in the Danon disease trial, have impacted investor confidence, which could make it more challenging to raise capital and potentially necessitate dilutive financing if approval delays persist or PRVs are not monetized.

Rocket Pharmaceuticals (RCKT) focuses on developing gene therapies for rare and devastating diseases, with several products targeting specific conditions, each with an identifiable addressable market.

Fanconi Anemia

The global Fanconi Anemia drug market, which includes gene therapies, was valued at approximately USD 385 million in 2023 and is projected to reach USD 1.02 billion by 2031. Another estimate places the global Fanconi Anemia treatment market at USD 614.58 million in 2024, expecting it to grow to USD 957.58 million by 2032. The 7 major markets (7MM), which typically include the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, represented an addressable market of approximately USD 51 million in 2023, with the United States accounting for nearly 54% of this market.

Leukocyte Adhesion Deficiency-I (LAD-I)

The global leukocyte adhesion deficiency management market, which includes treatments for LAD-I, was estimated at USD 8.09 billion in 2023 and is projected to grow to USD 15.2 billion by 2033. In 2024, this market was valued at $8.07 billion and is expected to reach $11.25 billion by 2029. North America is a dominant region in this market, holding approximately 40.5% of the global market share by the end of the forecast period. Rocket Pharmaceuticals launched KRESLADI, a gene therapy for LAD-I, in 2025, with a reported price exceeding $2,000,000 per dose in the U.S.

Pyruvate Kinase Deficiency

The global pyruvate kinase (PK) deficiency market size was valued at USD 450.50 million in 2024 and is expected to reach USD 675.80 million by 2032. The market is projected to grow to USD 1.85 billion by 2035, with a compound annual growth rate of 7.32% from 2025 to 2035. North America is the largest market, accounting for approximately 55% of the global market share in 2024.

Danon Disease

The global Danon disease treatment market was valued at USD 1.647.18 billion in 2023 and is projected to reach USD 2.82 billion by 2030, exhibiting a compound annual growth rate of 6.50%. The prevalence of Danon disease is estimated to be between 15,000 and 30,000 patients across the United States and Europe.

Rocket Pharmaceuticals (RCKT) is poised for potential revenue growth over the next 2-3 years, primarily driven by the advancement and commercialization of its gene therapy pipeline. Key drivers include:

1. Commercialization of KRESLADI (marnetegragene autotemcel) for Leukocyte Adhesion Deficiency-I (LAD-I): The U.S. Food and Drug Administration (FDA) accepted the Biologics License Application (BLA) for KRESLADI for severe LAD-I, with a Prescription Drug User Fee Act (PDUFA) target action date of March 28, 2026. Commercial readiness for KRESLADI is also anticipated for March 2026, marking a significant step towards transitioning Rocket into a commercial-stage company and a near-term source of revenue.
2. Advancement and potential commercialization of RP-A501 for Danon Disease: The FDA has lifted the clinical hold on the pivotal Phase 2 trial for RP-A501, with the dosing of additional patients with a recalibrated dose expected to resume in the first half of 2026. This program is progressing toward regulatory milestones in 2026. Analysts project Rocket Pharmaceuticals to generate revenue starting in 2026, with an average forecast of $18.4 million, growing to $36.3 million in 2027, and $84.0 million in 2028, indicating anticipated contributions from its pipeline products.
3. Progress of RP-A601 for PKP2 arrhythmogenic cardiomyopathy (ACM): The Phase 1 clinical study of RP-A601 is moving forward, with initial data previously expected in the first half of 2025. This program represents a substantial market opportunity, estimated to affect approximately 50,000 individuals in the U.S. and Europe, making its continued advancement a key driver for future revenue. This program is also moving towards regulatory milestones in 2026.
4. Expansion of the pipeline with new gene therapy candidates: Rocket Pharmaceuticals plans to initiate clinical studies for RP-A701, a new gene therapy candidate for dilated cardiomyopathy, by mid-2026. The company also had plans to submit an Investigational New Drug (IND) application for BAG3-DCM in the first half of 2025, signaling ongoing pipeline expansion that could introduce additional revenue streams in the longer term.

Share Issuance

• Rocket Pharmaceuticals completed a public offering in December 2024, raising net proceeds of $182.5 million from the sale of approximately 15.2 million shares of common stock and pre-funded warrants.
• In September 2023, the company priced an underwritten public offering of common stock and pre-funded warrants, which was expected to generate approximately $175 million in gross proceeds.
• As of March 2026, Rocket Pharmaceuticals entered into an at-the-market (ATM) equity offering program, allowing it to sell up to $100 million of its common stock. This agreement replaced a previous ATM sales agreement.

Capital Expenditures

• In the fourth quarter of 2025, Rocket Pharmaceuticals invested $80,000 in capital expenditures for long-term assets and infrastructure, marking a 248.1% increase from the prior quarter.
• The company anticipates that its existing cash resources will be sufficient to fund operations and meet capital expenditure requirements into the second quarter of 2027.
• Capital expenditures are expected to support the production of AAV cGMP batches at the company's Cranbury, N.J. R&D and manufacturing facility.